Can a new drug combo outsmart triple-negative breast cancer?
NCT ID NCT07752550
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This phase 2 trial is investigating whether adding an experimental drug called retlirafusp alfa to standard chemotherapy or to another drug called fuzuloparib can improve outcomes for people with triple-negative breast cancer (TNBC). The study includes two groups: one with early-stage disease receiving treatment before surgery, and another with advanced or metastatic disease. The main goals are to see how well the combinations shrink tumors and whether they are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Retlirafusp alfa combined with chemotherapy (nab-paclitaxel or TP-AC) or fuzuloparib
- What this could lead to
- If effective, this combination could offer a new treatment option for triple-negative breast cancer, potentially improving tumor shrinkage and response rates.
- What could go wrong
- This is an early-phase exploratory trial, so results may not confirm benefit. Combination treatments can also increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150081, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?
- Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer?